Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001047458 | SCV001211420 | uncertain significance | Fanconi anemia complementation group O | 2019-03-29 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with RAD51C-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with serine at codon 87 of the RAD51C protein (p.Ala87Ser). The alanine residue is highly conserved and there is a moderate physicochemical difference between alanine and serine. |
| Ambry Genetics | RCV002436580 | SCV002745472 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-03-27 | criteria provided, single submitter | clinical testing | The p.A87S variant (also known as c.259G>T), located in coding exon 2 of the RAD51C gene, results from a G to T substitution at nucleotide position 259. The alanine at codon 87 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |